With this project, PAM Theragnostics aims to develop a preventive therapy for Alzheimer’s Disease (AD). Our goals are the development of easy and reliable tools for early diagnosis and prediction of AD as well as to provide a safe and cost-effective biomarker guided therapy for the Alzheimer patients. Our main focus lies on vascular contributions in AD-development with the PAM enzyme being the main therapeutic target. The preclinical stage of our research and development project is funded by the European Regional Development Fund (Europäischer Fond für regionale Entwicklung – EFRE) and the Federal State of Brandenburg under the ProFIT Brandenburg program (Programm zur Förderung von Forschung, Innovation und Technologien).
Grand Nr.: 80256636, 80256637